Filament Supplies Botanical Psilocybin To Canadian Researchers, Inks Global Licensing Deal
Portfolio Pulse from Lara Goldstein
Filament Health (OTCQB:FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research. The company will donate its pharma-grade botanical psilocybin drug candidate PEX010 for the trials. Filament has also entered into an exclusive global licensing agreement with NeoLumina Bioscience for PEX010 and its associated IP to be developed for eating disorders. Filament will receive milestone payments and future commercial royalties on a percentage of net sales.
July 07, 2023 | 7:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Filament Health's involvement in two clinical studies and a global licensing deal with NeoLumina Bioscience could potentially boost its profile and revenues.
Filament Health's involvement in two clinical studies and a global licensing deal with NeoLumina Bioscience could potentially boost its profile and revenues. The company's drug candidate PEX010 is being used in these studies and the licensing deal, which could lead to increased demand for the drug and higher revenues for Filament. Additionally, the company's involvement in these high-profile projects could raise its profile in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100